New siRNA drug ADX-626 tested in humans for first time

NCT ID NCT07081503

Recruiting now Knowledge-focused Sponsor: ADARx Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This early-stage study is testing a new drug called ADX-626 in 44 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo (saline). The study does not aim to treat any disease, but to gather important safety information for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ADX-626 (siRNA drug)
What this could lead to: If successful, this early study could pave the way for future trials of ADX-626 in specific diseases.
What could go wrong: This is a very early Phase 1 study in healthy people, so it won't show if the drug treats any disease. Side effects are possible, and the drug may not work as hoped in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULT PARTICIPANTS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Richmond Pharmacology
RECRUITING

London, SE1 1YR, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.